Patents by Inventor Mei-Huei T. Lai

Mei-Huei T. Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6001810
    Abstract: The present invention provides antiretroviral methods using the compounds of formula (I)X-X1-P1-Val-Z-Leu-P2-Ywherein:Z is Statine or ACHPA;and when Z is Statine,X is H-Pro-paF, H-Pro-His, Ac-Tyr, Ac-NA, Ac-Trp, Ac-YOM, Ac-Phe, Ac-paF, H-His, Ac-His or Ac-Gly-Tyr-YOM,X1 is Pro Ser or Ac,P1 is Phe, paF or YOM,P2 is Phe or Leu, andY is NH.sub.2, paF--NH.sub.2, His--NH.sub.2, Phe--NH.sub.2 or Tyr-Lue--NH.sub.2,provided that when X1 is Ac then there is no X residue;and when Z is ACHPA,X is H-Pro-His, H-Pro-paF, Ac-paF or Ac-His,P1 is Phe,P2 is Phe, andY is paF--NH.sub.2 and His--NH.sub.2.The invention further provides methods for determining the retroviral protease inhibitory activity of compounds using viral polypeptides made using recombinant DNA techniques.
    Type: Grant
    Filed: August 31, 1990
    Date of Patent: December 14, 1999
    Assignee: Eli Lilly and Company
    Inventors: Kwan Yuk Hui, Mei-Huei T. Lai
  • Patent number: 5270040
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce subfragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 1, 1992
    Date of Patent: December 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. R. Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Patent number: 5235039
    Abstract: An assay method for the rapid determination of hydrolytic enzyme activity in large numbers of samples is provided which comprises bonding a resin-binding compound, such as biotin, to one side of the scissile bond of the substrate and a reporter molecule, such as a fluorescence marker, to the opposite side of the scissile bond, incubating the modified substrate and the enzyme in multiple well plates, e.g. 96-well plates, optionally in the presence if a test inhibitor or activator compound transferring the incubation solutions to a second multiple well plate having upper and lower chambers separated by a porous membrane the upper chamber of which contains resin beads capable of binding with the resin-binding compound, filtering and washing the wells of the second plate and reading the emission from the plates. The invention also provides protease substrates for HIV-1 protease, vertebrate stromelysin and derivatives thereof which are useful in the assay method.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: August 10, 1993
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Mei-Huei T. Lai, Joseph V. Manetta, John R. Sportsman, Sau-Chi B. Yan
  • Patent number: 5151268
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 5, 1988
    Date of Patent: September 29, 1992
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Patent number: 4775624
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: February 8, 1985
    Date of Patent: October 4, 1988
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Shelia P. Little, George L. Long, Robert F. Santerre